Correlation of body mass index to Ghrelin and IGF-1 among children with short stature¹

Abstract

Objective:

To assess the BMI among children with Growth Hormone Deficiency (GHD) and Idiopathic Short Stature (ISS) and its correlation to ghrelin, Growth Hormone (GH), and Insulin-like Growth Factor-1 (IGF-1) levels.

Methods:

A cross-sectional descriptive study in which 42 patients attending the Pediatric endocrine clinic were enrolled, allocated into two groups: group I: GHD children; group II: ISS children. Ghrelin, IGF-1 and GH in both groups were measured.

Results:

Ghrelin was significantly higher among GHD group (p < 0.001). Overall, there was a strong negative correlation between IGF-1 and ghrelin (r = -0.977, p-value = < 0.001) while a moderate positive correlation between ghrelin and BMI (r = 0.419, p-value = 0.006). There was a weak positive non-significant correlation between IGF-1 and BMI (r = 0.276, p-value = 0.077). In GHD group, there was a weak positive non-significant correlation between ghrelin and GH_max measurement (r = 0.052, p-value = 0.824), while a weak negative non-significant correlation between both variables in ISS group (r = -0.243, p-value = 0.288). In GHD group, there was a moderate positive correlation between ghrelin and BMI (r = 0.500, p-value = 0.021), but weak negative non-significant correlation between both variables in ISS group (r = -0.255, p-value = 0.265).

Conclusion:

There was a negative feedback loop between ghrelin and IGF-1, whereas a positive feedback between ghrelin and BMI. BMI was more affected in the ISS group but was non-signifi-cantly correlated with ghrelin. There was no significant compensatory response of ghrelin suggesting its contribution to the pathogenesis of ISS.

KEYWORDS
Ghrelin; IGF-1; Short stature; ISS; BMI; GHD

Introduction

Idiopathic short stature (ISS) is recognized as a clinical description, not a disease. There is no identifiable pathological cause making it a normal variant of growth with height less than 2 SD below the mean height corresponding to the same age, sex and ethnicity.¹ In addition, management remains challenging with many therapeutic options on an individual basis.

Ghrelin is a pleiotropic gut hormone controlling the gutbrain axis. It influences the secretion of growth hormone as one of its actions.² it is considered as a potent appetite stimulator and believed it may affect growth through insulin-like growth factor-1 (IGF-1) production through growth hormone secretion as well as enhancing the food intake through the orexigenic effect.³

Variable results have been reported when trying to assess the negative feedback loop between GH/IGF-1 axis and ghrelin.⁴

The current study aimed at measuring the correlation between ghrelin, growth hormone (GH), and IGF-1 levels and the anthropometric measurements among children with short stature in order to find out whether ghrelin influences nutritional status through GH/IGF-1 axis.

Methods

A cross-sectional descriptive study was conducted at the Pediatric endocrine clinic, Suez Canal University Hospitals from December 2017 to October 2018.

Patients were enrolled in this study after History taking, clinical examination and laboratory tests. The proposal for this study was approved by the Research Ethics Committee, faculty of medicine at Suez Canal University. Written informed patient consent was obtained from each subject before the study.

Children presented with proportionate short stature according to the Egyptian growth chart, of both genders, aged under 10 years were included. Children with familial short stature, chronic diseases, clinical syndromes (e.g., Turner), hormonal deficiency other than growth hormone (thyroid.. .etc), or skeletal dysplasia were excluded.

Patients were subjected to auxological assessment of weight (using a Seca weighing scale), height (using a stadiometer), and body mass index (kg/m²). The results were plotted on the WHO Z-score available for the corresponding age and gender.

Bone age was also done and calculated according to Greulich-Pyle’s standards.

Under complete aseptic conditions, peripheral venous blood was collected and all of the following were measured: ghrelin levels, IGF-1 and thyroid profile.

Growth hormone provocation was done initially by clonidine to all the patients, and if Peak GH concentration (GH_max) below 10 ng/mL, then the authors proceeded to insulin tolerance test (ITT).

The study population was divided into 2 groups:

• • Group I: Growth hormone deficiency group (GHD) children

Defined as height more than 2 standard deviation below the mean of the corresponding age and gender, with delayed bone age more than 1 year and GH_max below 10 ng/mL in two growth hormone provocation tests.⁵

• • Group II: idiopathic short stature (ISS) children

Defined as height more than 2 standard deviation below the mean of the corresponding age and gender, and provoked growth hormone (GH_max ≥ 10 ng/dL) without other causes of short stature.¹

The collected data were organized, tabulated and statistically analyzed using statistical package for social sciences (SPSS) version 21 (SPSS Inc, Chicago, USA), running on IBM compatible computer. For qualitative data, frequency and percent distributions were calculated. For quantitative data, mean and standard error (SE) were calculated.

Results

This study included a total of 42 short stature children under the age of 10 years old. They were divided into two equal groups, the GHD group (group I) and the ISS (group II). Both groups were matched regarding age in years (7.48 ± 1.66, 7.43 ± 1.47 respectively) as well as gender and family history. On the other both groups differed significantly regarding weight p ≤ 0.001, height p = 0.04, body mass index (BMI) p = 0.01 and bone age (p = 0.002)

GHD was more affected in bone age (4.57 ± 1.16 years), the SDS of height, and weight (-3.17 ± 0.17, -2.92 ± 0.27) respectively. However, BMI-SDS (-0.63 ± 0.07) was higher than the ISS group (-0.68 ± 0.06).

The ISS bone age, the SDS of height and weight were (5.71 ± 1.13 years, -2.59 ± 0.15, -2.75 ± 0.25) respectively.

There were statistically significant differences (p ≤ 0.001) between all of the growth hormone measurements after clonidine induction. The Peak GH concentration (GH_max) for the ISS group was nearly five times higher than the corresponding value in the other group (12.3 ± 0.62, 2.2 ± 0.25) ng/mL respectively.

There were statistically significant differences (p ≤ 0.001) between study groups regarding levels of insulin-like growth factor-1 and ghrelin, which was the expected physiological response (Fig. 1).

Figure 1
Graph comparing study groups with Insulin-like growth factor-1 (p ≤ 0.001) and ghrelin (p ≤ 0.001).

The whole study population showed a strong negative statistically significant correlation between insulin-like growth factor-1 and ghrelin (r = -0.977, p-value ≤ 0.001) as well as between ghrelin and GH_max measurement in the whole study population (r = -0.993, p-value ≤ 0.001). However, there was a strong positive statistically significant correlation between IGF-1 and GH_max in the whole study population (r= 0.976, p-value ≤ 0.001).

There was a moderate positive statistically significant correlation between ghrelin and BMI in the whole study population (r = 0.419, p-value = 0.006). the correlation was preserved in GHD group (r = 0.500, p-value = 0.021). on the contrary in ISS group, there was a weak positive non-significant correlation between both variables (r = 0.106, p-value = 0.648) (Fig. 2).

Figure 2
Scatterplots showing the relation between ghrelin and body mass index in the whole population and each study group, separately.

The correlation between IGF-1 and BMI revealed a weak positive non-significant correlation the whole study population (r = 0.276, p-value = 0.077). as well as in GHD group (r = 0.144, p = 0.534) There is a weak negative non-significant correlation between both variables in ISS group (r = -0.255, p-value = 0.265) (Fig. 3).

Figure 3
Scatterplots showing the relation between insulin-like growth factor-1 and body mass index in the whole study population and each study group, separately.

The blunted response of ghrelin with no significant compensatory response may play a role in the pathogenesis of ISS.

There was no significant correlation with the other different variables of the study in the separate study groups except TSH which showed a negative significant correlation with the IGF-1 in the ISS group only (r = -0.630, p = 0.002) (Table 1).

Table 1
Correlations between Insulin-like growth factor-1 and ghrelin, and other study variables in each study group.

Groups		Growth hormone-deficient		Idiopathic short stature
Variables	Parameters	Insulin-like growth factor-1 (ng/dL)	Ghrelin (pg/mL)	Insulin-like growth factor-1 (ng/dL)	Ghrelin (pg/mL)
Age (years)	r	-0.098	-0.419	-0.031	-0.307
	p-value	0.673	0.059	0.893	0.175
Height (SDS)	r	-0.325	-0.069	0.090	-0.134
	p-value	0.151	0.767	0.698	0.562
Weight (SDS)	r	0.217	-0.087	-0.069	0.038
	p-value	0.346	0.708	0.767	0.870
BMI (SDS)	r	0.144	0.500	-0.255	0.106
	p-value	0.534	0.021	0.265	0.648
Bone age (years)	r	0.275	-0.118	-0.031	-0.307
	p-value	0.228	0.609	0.893	0.175
Hemoglobin (g/dL)	r	0.187	-0.237	0.015	0.331
	p-value	0.417	0.301	0.950	0.143
GHBasal (ng/mL)	r	0.103	0.201	-0.162	0.260
	p-value	0.655	0.382	0.483	0.255
GHmax (ng/mL)	r	-0.096	0.052	-0.003	-0.243
	p-value	0.679	0.824	0.990	0.288
IGF-1 (ng/dL)	r	1.000	0.094	1.000	-0.170
	p-value	-	0.685	-	0.462
Ghrelin (pg/mL)	r	0.094	1.000	-0.170	1.000
	p-value	0.685	-	0.462	-
TSH (mIU/L)	r	-0.029	0.126	-0.630	-0.024
	p-value	0.899	0.585	0.002	0.918

• SDS, standard deviation score. GH_Basal, growth hormone measurement at time “0”. GH_max, Peak GH concentration. TSH, thyroid-stimulating hormone. BMI, Body mass index. IGF-1, Insulin-like growth factor-1.

Discussion

The role of endogenous ghrelin in the growth process of children is unclear. Ghrelin is one of the key hormones that influence the secretion of growth hormone with a significant orexigenic effect and accordingly metabolic effect.⁶

This study was conducted to determine the role of endogenous ghrelin as a pleiotropic hormone that may influence the growth in children with idiopathic short stature, versus those who are growth hormone deficiency. In the current study, it was obvious that the height is more affected in GHD group as expected, but the BMI is less affected in comparison to the ISS group.

Old and recent studies have shown that the BMI in children with GHD was higher than in children without at the time of diagnosis.⁷, ⁸ Some studies stated different effects of GH therapy on BMI; one stated that BMI increased with long-term GH therapy,⁹ another study revealed that no changes in BMI were detected along with the treatment.¹⁰

In 2020, Al Shaikh et al. found that BMI decreased significantly in ISS on GH therapy.¹¹ Despite the significant growth rate improvement,¹² the controversy between studies revealed that GH alone could not be relied upon to improve the BMI, suggesting the involvement of other factors.

Ghrelin is believed to have a significant role in adjusting the body energy status through stimulation of appetite. It was found to be compelled by neuro-endocrine mechanism, depressed with positive energy balance and increased with the negative balance status.¹³, ¹⁴

Yin et al. also commented in the context of lean and short children, that ghrelin may have reflected the nutritional status of those children rather than causing it.¹³

According to the present study, Ghrelin showed a significant negative correlation with IGF-1 in the studied population, but no significant correlation was found among the GHD group or ISS group separately.

Ghrelin and IGF-1 were found to have a negative correlation in both constitutional and familial short stature in a study conducted by Camurdan et al., which was explained by the possible stimulatory effects of low IGF-1 on ghrelin.¹⁵

On the contrary, Stawerska et al. observed that there was no correlation between ghrelin concentration and IGF-I SDS in prepubertal children known to be small-for-gestationalage (SGA) versus appropriate-for-gestational-age (AGA), despite assessing both with normal height and with short stature.¹⁶

In the context of nutritional status reflected by the BMI, the present study revealed that ghrelin was negatively correlated with height, weight and BMI within the studied children. There is a moderate positive statistically significant correlation between ghrelin and BMI (SDS) in the GHD group, while a weak negative non-significant correlation in the ISS group.

Wilasco et al. found that in healthy children, total ghrelin and des-acyl ghrelin values did not correlate with any anthropometric parameter and only acyl ghrelin had a weak negative correlation with SDS of the skin fold.¹⁷ However, Camurdan et al. study on the constitutional delay of growth and puberty (CDGP) and familial short stature (FSS) reported that Ghrelin was negatively correlated with chronological age, bone age, weight, height, height SDS, and BMI in short stature patients and controls.¹⁵ The same results were also reported among children with CDPG¹⁸ and ISS.⁶, ¹⁹

It is worth mentioning that, serum IGF-1 concentrations were positively correlated with age in prepubertal and early pubertal children while negatively correlated in late puberty.²⁰

In the current study, all the study’s patients were prepubertal; and despite being statistically insignificant, the correlation between IGF-1 and age was negative in the ISS group. Moreover, height SDS had an almost blunt response with IGF-1 while negatively correlated with Ghrelin in the same group.

This may be explained by the suboptimal nutritional status in ISS patients that affects both IGF-1 and Ghrelin. IGF-1 is influenced by a wide variety of factors; one of them is the nutritional status.²¹ Additionally, a compensatory elevation of ghrelin levels might represent an orexigenic stimulator⁶, ⁸, ¹³, ¹⁵, ²², ²³ and energy balance controller.²⁴, ²⁵, ²⁶, ²⁷, ²⁸ However, Wudy et al. in 2005 didn’t find any differences between poor and good eaters in relation to the total ghrelin.²²

Interestingly, the authors observed that thyroid-stimulating hormone (TSH) levels in the euthyroid ISS group had only a negative correlation with IGF-1 levels. The same was reported recently in the study done by Adamczewska et al., in 2020.²⁹ They found that ghrelin levels were closely related to TSH but the authors couldn’t find such a correlation in the present study’s sample.

On the contrary, Smyczynska et al., in 2010, found no correlation between the thyroid profile and IGF-1 before administration of rGH to GHD patients, and the response change after around 6 months of replacement therapy where there was a decrease in thyroid function without significant IGF-1 elevation.³⁰

“The contribution of the findings in deterioration of growth processes requires further studies”.²⁹

In conclusion; there was negative feedback between ghrelin and IGF-1 as well as GH, while positive feedback with BMI.

In the ISS group, BMI was more affected, with only a negative non-significant correlation with ghrelin. The results reflected the nutritional affection of the ISS patient. Additionally, the role of Ghrelin may contribute to idiopathic short stature pathogenesis.

Only TSH levels showed a negative significant correlation with IGF-1 levels in the euthyroid ISS.

A larger cohort is recommended to evaluate the contributing factors of short stature in ISS children and to check the role of ghrelin administration as a therapy in cases of ISS to improve their nutritional status and hence anthropometric measurements.

References

• ¹
  Cohen P, Rogol AD, Deal CL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008;93:4210–7.
• ²
  Perchard R, Clayton PE. Ghrelin and growth. Endocr Dev. 2017;32:74–86.
• ³
  Fernandez G, Cabral A, Andreoli MF, et al. Evidence supporting a role for constitutive ghrelin receptor signaling in fasting-induced hyperphagiain male mice. Endocrinology. 2018;159:1021–34.
• ⁴
  Matsuoka H, Hosoda H, Sugawara H, et al. Short-term secretory regulation of ghrelin during growth hormone provocative tests in prepubertal children with various growth hormone secretory capacities. Horm Res. 2005;64:274–9.
• ⁵
  Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86:361–97.
• ⁶
  Stawerska R, Czkwianianc E, Smyczynska J, HilczerM, Lewinski A. Nutritional status in short stature children is related to both ghrelin and insulin-like growth factor i concentrations. J Pediatr Gastroenterol Nutr. 2017;64:812–7.
• ⁷
  Cutfield WS, Lundgren F. Insulin-like growth factor I and growth responses during the first year of growth hormone treatment in KIGS patients with idiopathic growth hormone deficiency, acquired growth hormone deficiency, turner syndrome and born small for gestational age. Horm Res. 2009;71:39–45.
• ⁸
  Yackobovitch-Gavan M, Gat-Yablonski G, Shtaif B, et al. Growth hormone therapy in children with idiopathic short stature - the effect on appetite and appetite-regulating hormones: a pilot study. Endocr Res. 2019;44:16–26.
• ⁹
  Claessen KM, Appelman-Dijkstra NM, Adoptie DM, et al. Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab. 2013;98:352–61.
• ¹⁰
  Appelman-Dijkstra NM, Claessen KM, Roelfsema F, Pereira AM, Biermasz NR. Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. Eur J Endocrinol. 2013;169:R1–14.
• ¹¹
  Al Shaikh A, Daftardar H, Alghamdi AA, et al. Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center. Acta Biomed. 2020;91:29–40.
• ¹²
  Poyrazoğlu Ş, Akçay T, Arslanoğlu I, et al. Current practice in diagnosis and treatment of growth hormone deficiency in childhood: a survey from Turkey. J Clin Res Pediatr Endocrinol. 2015;7:37–44.
• ¹³
  Yin X, Li Y, Xu G, An W, Zhang W. Ghrelin fluctuation, what determines its production? Acta Biochim Biophys Sin. 2009; 41:188–97.
• ¹⁴
  van der Lely AJ, Tschöp M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev. 2004;25:426–57.
• ¹⁵
  Camurdan MO, Bideci A, Demirel F, Cinaz P. Serum ghrelin, IGF-I and IGFBP-3 levels in children with normal variant short stature. Endocr J. 2006;53:479–84.
• ¹⁶
  Stawerska R, Szalapska M, Hilczer M, Ghrelin LA. insulin-like growth factor I and adipocytokines concentrations in born small for gestational age prepubertal children after the catch-up growth. J Pediatr Endocrinol Metab. 2016;29:939–45.
• ¹⁷
  Wilasco MI, Goldani HA, Dornelles CT, et al. Ghrelin, leptin and insulin in healthy children: Relationship with anthropometry, gender, and age distribution. Regul Pept. 2012;173:21 -6.
• ¹⁸
  El-Eshmawy MM, Abdel Aal IA, El Hawary AK. Association of ghrelin and leptin with reproductive hormones in constitutional delay of growth and puberty. Reprod Biol Endocrinol. 2010;8: 153.
• ¹⁹
  Iñiguez G, Román R, Youlton R, Cassorla F, Mericq V. Ghrelin plasma levels in patients with idiopathic short stature. Horm Res Paediatr. 2011;75:94–100.
• ²⁰
  Löfqvist C, Andersson E, Gelander L, Rosberg S, Blum WF Albertsson Wikland K. Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age, and puberty. J Clin Endocrinol Metab. 2001;86:5870–6.
• ²¹
  Livingstone C. Insulin-like growth factor-I (IGF-I) and clinical nutrition. Clin Sci. 2013;125:265–80.
• ²²
  Wudy SA, Hagemann S, Dempfle A, et al. Children with idiopathic short stature are poor eaters and have decreased body mass index. Pediatrics. 2005;116:e52–7.
• ²³
  Gueorguiev M, Korbonits M. Genetics of the ghrelin system. Endocr Dev. 2013;25:25–40.
• ²⁴
  Pinsker JE, Ondrasik D, Chan D, et al. Total and acylated ghrelin levels in children with poor growth. Pediatr Res. 2011;69: 517–21.
• ²⁵
  Pantel J, Legendre M, Nivot S, et al. Recessive isolated growth hormone deficiency and mutations in the ghrelin receptor. J Clin Endocrinol Metab. 2009;94:4334–41.
• ²⁶
  Muhammad HF. Obesity as the sequel of childhood stunting: ghrelin and GHSR gene polymorphism explained. Acta Med Indones. 2018;50:159–64.
• ²⁷
  Mear Y, Blanchard MP, Defilles C, et al. Ghrelin receptor (GHS-R1a) and its constitutive activity in somatotroph adenomas: a new co-targeting therapy using GHS-R1a inverse agonists and somatostatin analogs. J Clin Endocrinol Metab. 2014;99: E2463–71.
• ²⁸
  Lim CT, Korbonits M. Paediatric endocrine aspects of ghrelin. Pediatr Endocrinol Rev. 2012;9:628–38.
• ²⁹
  Adamczewska K, Adamczewski Z, Lupinska A, Lewinski A, Stawerska R. Strong positive correlation between TSH and ghrelin in euthyroid non-growth hormone-deficient children with short stature. Molecules. 2020;25:3912.
• ³⁰
  Smyczynska J, HilczerM, Stawerska R, Lewinski A. Thyroid function in children with growth hormone (GH) deficiency during the initial phase of GH replacement therapy - clinical implications. Thyroid Res. 2010;3:2.

Publication Dates

• Publication in this collection
  06 June 2022
• Date of issue
  May-Jun 2022

History

• Received
  17 Jan 2021
• Accepted
  23 Apr 2021
• Published
  14 July 2021